CellSource Past Earnings Performance
Past criteria checks 1/6
CellSource has been growing earnings at an average annual rate of 18.6%, while the Life Sciences industry saw earnings growing at 24.8% annually. Revenues have been growing at an average rate of 21.4% per year. CellSource's return on equity is 3.9%, and it has net margins of 5.4%.
Key information
18.6%
Earnings growth rate
-31.7%
EPS growth rate
Life Sciences Industry Growth | 32.0% |
Revenue growth rate | 21.4% |
Return on equity | 3.9% |
Net Margin | 5.4% |
Last Earnings Update | 31 Oct 2024 |
Recent past performance updates
We Think That There Are More Issues For CellSource (TSE:4880) Than Just Sluggish Earnings
Dec 20Shaky Earnings May Not Tell The Whole Story For CellSource (TSE:4880)
Jun 20Recent updates
We Think That There Are More Issues For CellSource (TSE:4880) Than Just Sluggish Earnings
Dec 20Some CellSource Co., Ltd. (TSE:4880) Shareholders Look For Exit As Shares Take 25% Pounding
Dec 19A Look At The Fair Value Of CellSource Co., Ltd. (TSE:4880)
Aug 13Shaky Earnings May Not Tell The Whole Story For CellSource (TSE:4880)
Jun 20Revenue & Expenses Breakdown
How CellSource makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Oct 24 | 4,355 | 237 | 2,163 | 71 |
31 Jul 24 | 4,446 | 622 | 1,475 | 72 |
30 Apr 24 | 4,567 | 812 | 2,126 | 72 |
31 Jan 24 | 4,624 | 850 | 1,995 | 72 |
31 Oct 23 | 4,510 | 923 | 1,866 | 72 |
31 Jul 23 | 4,807 | 1,103 | 1,683 | 87 |
30 Apr 23 | 4,746 | 1,119 | 1,571 | 87 |
31 Jan 23 | 4,512 | 1,078 | 1,485 | 87 |
31 Oct 22 | 4,273 | 1,017 | 1,393 | 87 |
31 Jul 22 | 3,690 | 812 | 1,277 | 71 |
30 Apr 22 | 3,276 | 691 | 1,166 | 71 |
31 Jan 22 | 3,120 | 693 | 1,065 | 71 |
31 Oct 21 | 2,922 | 651 | 998 | 71 |
31 Jul 21 | 2,648 | 544 | 1,020 | 10 |
30 Apr 21 | 2,312 | 424 | 952 | 10 |
31 Jan 21 | 2,033 | 310 | 902 | 10 |
31 Oct 20 | 1,855 | 274 | 825 | 10 |
31 Jul 20 | 1,750 | 212 | 822 | 7 |
31 Oct 19 | 1,611 | 199 | 813 | 7 |
31 Oct 18 | 1,212 | 193 | 572 | 6 |
31 Oct 17 | 519 | 111 | 136 | 4 |
Quality Earnings: 4880 has a large one-off gain of ¥63.0M impacting its last 12 months of financial results to 31st October, 2024.
Growing Profit Margin: 4880's current net profit margins (5.4%) are lower than last year (20.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4880's earnings have grown by 18.6% per year over the past 5 years.
Accelerating Growth: 4880's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4880 had negative earnings growth (-74.3%) over the past year, making it difficult to compare to the Life Sciences industry average (1.4%).
Return on Equity
High ROE: 4880's Return on Equity (3.9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 02:52 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/10/31 |
Annual Earnings | 2024/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CellSource Co., Ltd. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |
Masatoshi Nagata | Ichiyoshi Research Institute Inc. |
Kyoichiro Shigemura | Nomura Securities Co. Ltd. |